Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alli available soon?

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline appears confident that issues raised in FDA's "approvable" letter for the weight-loss drug Alli (orlistat 60 mg) can be resolved swiftly. The firm "expects to respond to [FDA's April 6 approvable letter] shortly and to receive approval for the product" in the second half of 2006, the firm announces in a first-quarter earnings release April 27. The company previously has stated that it is aiming to make an OTC version of the weight-loss drug, sold by prescription as Xenical, available by mid 2006. The firm reported a strong first quarter during an earnings call, with Consumer Healthcare sales increasing 6% to $1.34 bil. ($1.75=£1) over the prior-year period. The increase was driven by sales growth in Europe and the international market, as sales in North America dropped 2%. Oral care sales grew 7% to $423.5 mil., driven primarily by Sensodyne's 21% sales growth; Aquafresh remained level at $127.75 mil. OTC drug sales increased 3% to $654.5 mil. for the quarter, while smoking cessation product revenues grew 5% to $162.7 mil...

Topics

UsernamePublicRestriction

Register

PS099319

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel